472 related articles for article (PubMed ID: 27114543)
1. Tryptophan-2,3-dioxygenase (TDO) inhibition ameliorates neurodegeneration by modulation of kynurenine pathway metabolites.
Breda C; Sathyasaikumar KV; Sograte Idrissi S; Notarangelo FM; Estranero JG; Moore GG; Green EW; Kyriacou CP; Schwarcz R; Giorgini F
Proc Natl Acad Sci U S A; 2016 May; 113(19):5435-40. PubMed ID: 27114543
[TBL] [Abstract][Full Text] [Related]
2. The kynurenine pathway modulates neurodegeneration in a Drosophila model of Huntington's disease.
Campesan S; Green EW; Breda C; Sathyasaikumar KV; Muchowski PJ; Schwarcz R; Kyriacou CP; Giorgini F
Curr Biol; 2011 Jun; 21(11):961-6. PubMed ID: 21636279
[TBL] [Abstract][Full Text] [Related]
3. Drosophila eye color mutants as therapeutic tools for Huntington disease.
Green EW; Campesan S; Breda C; Sathyasaikumar KV; Muchowski PJ; Schwarcz R; Kyriacou CP; Giorgini F
Fly (Austin); 2012; 6(2):117-20. PubMed ID: 22634544
[TBL] [Abstract][Full Text] [Related]
4. Targeting kynurenine 3-monooxygenase (KMO): implications for therapy in Huntington's disease.
Thevandavakkam MA; Schwarcz R; Muchowski PJ; Giorgini F
CNS Neurol Disord Drug Targets; 2010 Dec; 9(6):791-800. PubMed ID: 20942784
[TBL] [Abstract][Full Text] [Related]
5. Genetic alterations affecting the genes encoding the enzymes of the kynurenine pathway and their association with human diseases.
Boros FA; Bohár Z; Vécsei L
Mutat Res Rev Mutat Res; 2018; 776():32-45. PubMed ID: 29807576
[TBL] [Abstract][Full Text] [Related]
6. The kynurenine pathway and neurodegenerative disease.
Maddison DC; Giorgini F
Semin Cell Dev Biol; 2015 Apr; 40():134-41. PubMed ID: 25773161
[TBL] [Abstract][Full Text] [Related]
7. The kynurenine pathway in neurodegenerative diseases: mechanistic and therapeutic considerations.
Tan L; Yu JT; Tan L
J Neurol Sci; 2012 Dec; 323(1-2):1-8. PubMed ID: 22939820
[TBL] [Abstract][Full Text] [Related]
8. Kynurenine pathway in Parkinson's disease-An update.
Venkatesan D; Iyer M; Narayanasamy A; Siva K; Vellingiri B
eNeurologicalSci; 2020 Dec; 21():100270. PubMed ID: 33134567
[TBL] [Abstract][Full Text] [Related]
9. Involvement of the kynurenine pathway in human glioma pathophysiology.
Adams S; Teo C; McDonald KL; Zinger A; Bustamante S; Lim CK; Sundaram G; Braidy N; Brew BJ; Guillemin GJ
PLoS One; 2014; 9(11):e112945. PubMed ID: 25415278
[TBL] [Abstract][Full Text] [Related]
10. On the relationship between the two branches of the kynurenine pathway in the rat brain in vivo.
Amori L; Guidetti P; Pellicciari R; Kajii Y; Schwarcz R
J Neurochem; 2009 Apr; 109(2):316-25. PubMed ID: 19226371
[TBL] [Abstract][Full Text] [Related]
11. L-Tryptophan-kynurenine pathway enzymes are therapeutic target for neuropsychiatric diseases: Focus on cell type differences.
Fujigaki H; Yamamoto Y; Saito K
Neuropharmacology; 2017 Jan; 112(Pt B):264-274. PubMed ID: 26767951
[TBL] [Abstract][Full Text] [Related]
12. Galantamine-Memantine Combination and Kynurenine Pathway Enzyme Inhibitors in the Treatment of Neuropsychiatric Disorders.
Bai MY; Lovejoy DB; Guillemin GJ; Kozak R; Stone TW; Koola MM
Complex Psychiatry; 2021 Aug; 7(1-2):19-33. PubMed ID: 35141700
[TBL] [Abstract][Full Text] [Related]
13. Kynurenine 3-Monooxygenase Activity in Human Primary Neurons and Effect on Cellular Bioenergetics Identifies New Neurotoxic Mechanisms.
Castellano-Gonzalez G; Jacobs KR; Don E; Cole NJ; Adams S; Lim CK; Lovejoy DB; Guillemin GJ
Neurotox Res; 2019 Apr; 35(3):530-541. PubMed ID: 30666558
[TBL] [Abstract][Full Text] [Related]
14. Activation of the kynurenine pathway and increased production of the excitotoxin quinolinic acid following traumatic brain injury in humans.
Yan EB; Frugier T; Lim CK; Heng B; Sundaram G; Tan M; Rosenfeld JV; Walker DW; Guillemin GJ; Morganti-Kossmann MC
J Neuroinflammation; 2015 May; 12():110. PubMed ID: 26025142
[TBL] [Abstract][Full Text] [Related]
15. Tryptophan 2,3-dioxygenase, a novel therapeutic target for Parkinson's disease.
Boros FA; Vécsei L
Expert Opin Ther Targets; 2021 Oct; 25(10):877-888. PubMed ID: 34720020
[TBL] [Abstract][Full Text] [Related]
16. Dynamic changes in metabolites of the kynurenine pathway in Alzheimer's disease, Parkinson's disease, and Huntington's disease: A systematic Review and meta-analysis.
Fathi M; Vakili K; Yaghoobpoor S; Tavasol A; Jazi K; Hajibeygi R; Shool S; Sodeifian F; Klegeris A; McElhinney A; Tavirani MR; Sayehmiri F
Front Immunol; 2022; 13():997240. PubMed ID: 36263032
[TBL] [Abstract][Full Text] [Related]
17. Kynurenic acid in neurodegenerative disorders-unique neuroprotection or double-edged sword?
Ostapiuk A; Urbanska EM
CNS Neurosci Ther; 2022 Jan; 28(1):19-35. PubMed ID: 34862742
[TBL] [Abstract][Full Text] [Related]
18. Abnormal kynurenine pathway of tryptophan catabolism in cardiovascular diseases.
Song P; Ramprasath T; Wang H; Zou MH
Cell Mol Life Sci; 2017 Aug; 74(16):2899-2916. PubMed ID: 28314892
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic potential of targeting kynurenine pathway in neurodegenerative diseases.
Shen H; Xu X; Bai Y; Wang X; Wu Y; Zhong J; Wu Q; Luo Y; Shang T; Shen R; Xi M; Sun H
Eur J Med Chem; 2023 May; 251():115258. PubMed ID: 36917881
[TBL] [Abstract][Full Text] [Related]
20. Expression of tryptophan 2,3-dioxygenase and production of kynurenine pathway metabolites in triple transgenic mice and human Alzheimer's disease brain.
Wu W; Nicolazzo JA; Wen L; Chung R; Stankovic R; Bao SS; Lim CK; Brew BJ; Cullen KM; Guillemin GJ
PLoS One; 2013; 8(4):e59749. PubMed ID: 23630570
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
